. Author manuscript; available in PMC: 2020 Sep 16.

Published in final edited form as: Cancer Treat Res Commun. 2019 Sep 5;21:100159. doi: 10.1016/j.ctarc.2019.100159

Table 1.

Patient demographics and laboratory measurements.^*

	Multiple myeloma n = 100	Control n = 100	p-value
Age (years)	61 (55-69)	65 (54-72)	0.09
Female, n (%)	46 (46)	76 (76)	< 0.01
BMI (kg/m²)	28 (25-32)	26 (22-30)	0.02
Creatinine (mg/dL)^**	1 (0.8-1.5)	0.9 (0.7-1.1)	< 0.01
Phosphorus (mg/dL)^**^†	3.7 (3-4.4)	3.4 (2.7-4)	0.047
Albumin (g/dL)^**	3.8 (3.3-4.1)	3.3 (2.7-3.9)	< 0.01
Ionized calcium	5.17 (4.81-5.45) mg/dL	5.09 (4.45-5.69) mg/dL	0.64
Ionized calcium	1.29 (1.2-1.36) mmol/L	1.27 (1.11-1.42) mmol/L	0.64
Corrected calcium (mg/dL)	9.8 (9.1-10.8)	9.8 (9.1-11.6)	0.29
Paraprotein (g/dL)^‡§	0.5 (0.2-1.6)	N/A	N/A
Free kappa light chains (mg/dL)^‡	1.27 (0.5-2.95)	N/A	N/A
Free lambda light chains (mg/dL)^‡	1.58 (0.9-10)	N/A	N/A

IQR, interquartile range; BMI, body mass index; N/A, not applicable

Median (IQR), unless noted otherwise

^**

Measured within 24 hours of calcium measurements.

^†

Data available for 70% of multiple myeloma group patients and 97% of control group patients.